

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 254 962 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
06.11.2002 Bulletin 2002/45

(51) Int Cl.7: **C12P 21/02, C12N 15/67**

(21) Application number: **02009650.9**

(22) Date of filing: **27.04.2002**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(71) Applicants:
• **Roche Diagnostics GmbH**
68305 Mannheim (DE)
• **F. HOFFMANN-LA ROCHE AG**
4070 Basel (CH)

(30) Priority: **30.04.2001 DE 10121235**

(72) Inventor: **Buchner, Johannes, Prof. Dr.**
93346 Ihrlersstein (DE)

(54) **Method for the expression of proteins in in vitro translation systems with coexpression of folding helper proteins**

(57) The present invention concerns a method for the expression of target proteins in *in vitro* translation systems, characterized in that folding helper proteins are co-expressed in this system. The co-expressed folding helper proteins are selected from one or several of

the following protein classes: Hsp70, Hsp60, Hsp90, Hsp100 protein family, the family of small heat shock proteins and isomerases.

EP 1 254 962 A1

Description

[0001] The present invention concerns a method for the expression of target proteins in *in vitro* translation systems, characterized in that folding helper proteins are co-expressed in this system. The co-expressed folding helper proteins are selected from one or several of the following protein classes: Hsp70-, Hsp60-, Hsp90-, Hsp100-protein family, the family of small heat shock proteins and isomerases.

[0002] The folding of large oligomeric proteins *in vitro* is frequently impaired by the occurrence of aggregation (Jaenicke and Rudolph, 1986; Buchner, 1996; Jaenicke, 1997). Aggregation is an alternative route to normal folding which competes with correct folding and association. The reason for the aggregation is the formation of incorrect intermolecular interactions (Kiefhaber et al., 1991) which ultimately lead to the formation of heterogeneous aggregates in which the polypeptide chains contained therein are irreversibly lost. It is possible to minimize aggregation *in vitro* as an undesired side reaction by physico-chemical parameters such as protein concentration, solvent conditions, temperature or ionic strength (Jaenicke and Rudolph, 1989; Kiefhaber et al., 1991; Buchner, 1996; Jaenicke, 1997). In contrast the external conditions for all proteins are constant *in vivo*. An *E. coli* cell achieves an apparent folding yield of almost 100 % despite the enormous rate of synthesis of ca. 60000 polypeptide chains per minute (Lorimer, 1996). Although misfolding and incorrect assembling of proteins also occurs *in vivo* (Hurtley and Helenius, 1989; Pelham, 1989; Helenius et al., 1992), this is minimized by several endogenous cell factors. Chaperones or heat shock proteins prevent unspecific aggregation (Buchner et al., 1996) and misfolded proteins or proteins that fold too slowly are degraded (Gottesman and Maurizi, 1992). Mutagenesis studies on heat shock-deficient *E. coli* strains showed that so-called *inclusion bodies* occur at elevated growth temperatures (Grangerov et al., 1991). Independently thereof it was shown that the formation of *inclusion bodies* resulting from the overexpression of recombinant proteins in *E. coli* can be efficiently suppressed by a simultaneous overexpression of endogenous cell heat shock proteins (Goloubinoff et al., 1989; Dale et al., 1994; Amrein et al., 1995). Protein import into cellular compartments such as mitochondria also depends on heat shock proteins located in the organelles. On the basis of these observations the folding of proteins can be regarded as a spontaneous process which is assisted by folding helper proteins (Horwich et al., 1993; Hendrick and Hartl, 1993; Georgopoulos and Welch, 1993). Hence the precise interplay between these endogenous cell factors reduces incorrect folding processes and promotes the correct folding of polypeptides (Buchner, 1996; Beißinger and Buchner, 1998; Hartl, 1998).

[0003] Another important difference between folding *in vitro* and *in vivo* is that proteins in the cell are folded

vectorially from the N- to the C-terminus (Bergman and Kühl, 1979; Braakman et al., 1991). This process occurs during translation or translocation. The onset of structure formation already occurs while the polypeptide is still at the ribosome or during translocation. This also means that some hydrophobic regions and other potential interaction regions of the polypeptide have to wait for their interaction partner that is still to be synthesized. However, non-appropriate interactions can occur during this synthesis process that can only be reversed under certain conditions and can lead to aggregation reactions. On the other hand disulfide bridges can already be detected in this state in immunoglobulins, serum albumin and haemagglutinin (Bergman & Kühl, 1979; Peeters & Davidson, 1982; Braakman et al., 1991). It was shown that folding helper proteins of the Hsp70-chaperone family can already interact with the nascent polypeptide chain during translation on the ribosome (Egers et al., 1997; Frydman et al., 1994; Hansen et al., 1994; Welch et al., 1997). Many other processes such as the import of cytosolically synthesized polypeptide chains into mitochondria are dependent on folding helper proteins (Dekker and Pfanner, 1999). In this connection proteins can only be transported through one or both mitochondrial membranes in a linear unfolded state. In this process molecular chaperones are involved in the unfolding and stabilization of the unfolded state on the cytosolic site of the membrane as well as in the transport and folding in the mitochondria.

[0004] In the case of folding *in vitro* the formation and isomerization of disulfide bridges and the cis/trans-isomerization of prolines are in particular the rate determining folding steps. These folding steps are catalysed by folding assistants in the cell. Protein disulfide isomerases such as PDI or DsbA accelerate redox reactions of cysteines and disulfides in polypeptides depending on the redox conditions (Wunderlich and Glockshuber, 1993; Bardwell, 1997). The acceleration of this folding step reduces the concentration of intermediates during the folding process. This reduces concentration-dependent aggregation and increases the folding yield (Weissman and Kim, 1993; Lillie et al., 1994). Peptidyl-prolyl-cis/isomerases (PPI) catalyse isomerization between the cis and trans form of peptide bonds in front of proline residues in polypeptide chains. In contrast to all other peptide bonds in native proteins, these can be present in their cis configuration (Schmid, 1997).

[0005] The *E. coli* lysate that is frequently used in *in vitro* translation systems is a natural and optimal system for protein folding. But in contrast to a functional cell, the amount of required chaperones is not automatically adapted to the synthesis output of the translation apparatus. The resulting overloading of the folding machinery in many cases results in the aggregation of the target protein. Various components of the folding machinery can be responsible for this inefficient folding depending on the target protein.

[0006] The object of the present invention was to in-

crease the yield of target protein in an *in vitro* translation system by preventing aggregation of the target protein by providing the required chaperones in an adequate quantity in the *in vitro* translation system. This should at the same time increase the efficiency of the *in vitro* translation system.

[0007] The object is achieved according to the invention by a method for the expression of target proteins in *in vitro* translation systems characterized in that folding helper proteins are co-expressed in this system. The co-expressed folding helper proteins are selected from one or several of the following protein classes: Hsp60, Hsp70, Hsp90, Hsp100 protein family, family of the small heat shock proteins and isomerases.

[0008] Molecular chaperones are the largest group of folding-assisting proteins and are understood according to the invention as folding helper proteins (Gething and Sambrook, 1992; Hartl, 1996; Buchner, 1996; Beißinger and Buchner, 1998). Due to their overexpression under stress conditions, most molecular chaperones can also be allocated to the group of heat shock proteins (Georgopoulos and Welch, 1993; Buchner, 1996), this group is also understood according to the invention as a folding helper protein.

[0009] Important folding helper proteins which are encompassed by the present invention are elucidated in more detail in the following. The group of molecular chaperones can be divided on the basis of sequence homologies and molecular masses into five non-related protein classes i.e. the Hsp60, Hsp70, Hsp90, Hsp100 protein families and the family of the small heat shock proteins (Gething and Sambrook, 1992; Hendrick and Hartl, 1993).

• Hsp60

[0010] The best investigated chaperone overall is GroEL which is a member of the Hsp60 family from *E. coli*. Members of the Hsp60 families are also referred to as chaperonins and are divided into two groups. GroEL and its co-chaperone GroES and their strongly homologous relatives from other bacteria as well as mitochondria and chloroplasts form the group of I chaperonins (Sigler et al., 1998; Fenton and Horwich, 1994). The Hsp60 proteins from the eukaryotic cytosol from Archaeobacteria together form the group II chaperonins (Gutsche et al., 1999). The Hsp60 proteins in both groups have a similar oligomeric structure. In the case of GroEL and the other group I chaperonins, 14 GroEL subunits associate to form a cylinder composed of two heptamer rings whereas the heptamer ring structure in the group II chaperonins from Archaeobacteria is usually composed of two different subunits. In contrast members of the group II chaperonins from eukaryotic cytosol such as the CCT complex from yeast are composed of eight different subunits with an exactly defined organisation (Liou and Willison, 1997). Non-native proteins can be intercalated and bound in the central cavity of this cylinder. The

co-chaperone GroES also forms a heptameric ring and binds in this form to the poles of the GroEL cylinder. However, this binding of GroES results in a limitation of the substrate binding depending on its size 10-55 kDa; (Ewalt et al., 1997). The substrate binding is regulated by ATP-binding and hydrolysis.

• Hsp70

[0011] In addition to members of the Hsp60 family, the Hsp70 proteins also bind to the nascent polypeptide chain (Beckman et al., 1990; Welch et al., 1997). There are usually several constitutively expressed and stress-induced members of the Hsp70 families present in prokaryotic as well as in eukaryotic cells (Vickery et al., 1997; Welch et al., 1997). Apart from their involvement in protein folding directly on the ribosome, these proteins are also involved in the translocation of proteins through cell and organelle membranes (Schatz & Doberstein, 1996). It was shown that proteins can only be transported through membranes in an unfolded or partially folded state (Hannavy et al., 1993). During the translocation process in organelles, it is above all the members of the Hsp70 family that are involved in unfolding and stabilization on the cytosolic side as well as in the refolding on the organelle side (Hauke and Schatz, 1997). In all these processes the ATPase activity of Hsp70 is essential for the function of the protein. A characteristic feature of the Hsp70 system is the control of the activity by co-chaperones (Hsp40; DnaJ) in which the equilibrium between substrate binding and release is influenced by specific modulation of the ATPase activity (Bukau and Horwich, 1998).

• Hsp90

[0012] About 1 % of the soluble protein in the eukaryotic cytosol is Hsp90 which is thus one of the most strongly expressed proteins (Welch and Feramisco, 1982). The members of this family mainly act in multimeric complexes where they recognize numerous important signal transduction proteins with similar structures to the native proteins. Binding to Hsp90 and its partner proteins stabilizes these structures and thus facilitates the binding of ligands to the signal proteins. In this manner the substrates can attain their active conformation (Sullivan et al., 1997; Bohlen et al., 1995; Buchner, 1999).

• Hsp100

[0013] Recently the Hsp100 chaperones have been particularly distinguished by their ability in cooperation with the Hsp70 chaperones to dissociate already formed aggregates (Parsell et al., 1994; Goloubinoff et al., 1999; Mogk et al., 1999). Although their main function appears to be the mediation of thermotolerance (Schirmer et al., 1994; Kruger et al., 1994), some mem-

bers such as ClpA and ClpB together with the protease-subunit ClpP mediate the proteolytic degradation of proteins (Gottesman et al., 1997).

• sHsps

[0014] The fifth class of chaperones the small heat shock proteins (sHsps) are a very divergent family of heat shock proteins which are found in almost all organisms. The reason for thus naming this family of chaperones is their relatively low monomeric molecular weight of 15-40 kDa. However, sHsps usually exist in the cell as high-oligomeric complexes containing up to 50 subunits which have been observed to have molecular masses of 125 kDa to 2 Mda (Spector et al., 1971; Arrigo et al., 1988; Andreasi-Bassi et al., 1995; Ehrnsperger et al., 1997). Like other chaperones, the sHsps can suppress the aggregation of proteins *in vitro* (Horwitz, 1992; Jakob et al., 1993; Merck et al., 1993; Jakob and Buchner, 1994; Lee et al., 1995; Ehrnsperger et al., 1997b). In this process sHsps bind up to one substrate molecule per subunit and hence have a higher efficiency than the model chaperone GroEL (Jaenicke and Creighton, 1993; Ganea and Harding, 1995; Lee et al., 1997; Ehrnsperger et al., 1998a). Under stress conditions the binding of non-native protein to sHsps prevents the irreversible aggregation of the proteins. Binding to sHsps holds the proteins in a soluble folding-competent state. After restoring physiological conditions the non-native protein can be detached from the complex with sHsp by ATP-dependent chaperones like Hsp70 and reactivated.

• Isomerases

[0015] Folding catalysts from the class of peptidyl-prolyl-cis/trans isomerases and members of the disulfide isomerases for example come into consideration as isomerases for the method according to the invention.

[0016] Folding helper proteins which function in the same manner or in a similar manner to the folding helper proteins described above are also encompassed by the present invention.

[0017] According to the present invention it is preferred that the co-expressed folding helper proteins are members of the Hsp60 protein family. Furthermore co-chaperones are preferably additionally co-expressed. According to the method according to the invention it is particularly preferred that Hsp60 as a folding helper protein and Hsp10 as a co-chaperone are co-expressed. It is particularly preferred that the co-expressed folding helper protein is GroEL. A method is particularly preferred in which GroEL/GroES are co-expressed.

[0018] Another preferred variant of the method is that the co-expressed folding helper proteins are members of the Hsp70 protein family. Furthermore co-chaperones are preferably co-expressed in addition. In this variant

it is particularly preferred that the co-expressed folding helper protein is a human Hsp70 protein. In particular it is then preferred that Hsp70 as a folding helper protein and Hsp40 as a co-chaperone are co-expressed. According to the method of the invention, Hsp70 from humans and Hdj 1 (Hsp40 from humans) are most preferably co-expressed in this variant.

[0019] According to the invention the target proteins can be all types of prokaryotic and eukaryotic proteins and also archaeal proteins. The expression of secretory proteins and membrane proteins was previously particularly problematic in *in vitro* transcription/translation systems especially when folding helper proteins were not present in adequate amounts. Although the successful expression of lipoproteins and membrane proteins has been described in the prior art, it is subject to considerable limitations (Huppa and Ploegh, 1997; Falk et al., 1997). The method according to the invention is particularly suitable for the expression of lipoproteins and membrane proteins and secretory proteins as the target protein since folding helper proteins can be provided by the co-expression in an adequate amount.

[0020] An advantage of the method according to the invention is in particular that the increase in the volume yield of the target protein in *in vitro* transcription/translation systems occurs on a preparative scale.

[0021] *In vitro* translation systems which can be the basis for the present invention and in particular coupled *in vitro* transcription/translation systems are described in more detail in the following section. At present the most efficient systems are based on *E. coli*, rabbit reticulocyte or wheat-germ lysates (Spirin, 1990; Stiege and Erdman, 1995). They are usually used as batch reactions with a defined reaction volume. *E. coli*-based reactions can be used in a temperature range of 24-38°C. The 30S supernatant of *E. coli* lysates is usually used for these batch processes which, due to the high content of endogenous mRNA, has to be treated with RNase before using it for *in vitro* translation (Zubay, 1973). Reactions based on wheat-germ lysates are normally only used in a temperature range of 20-27°C (Tulin et al., 1995) but have the advantage over *E. coli* lysates that they can be used directly for the expression of exogenous expression templates due to the low level of endogenous mRNA. Reticulocyte lysates are prepared by direct lysis of anaemic rabbit blood from which the endogenous mRNAs are removed by RNase treatment. These systems are usually used for processes in a temperature range of 30-38°C (Pelham and Jackson, 1976). However, it should be noted that the working temperature not only has an effect on the translation processes but also that the folding of the target proteins is extremely dependent on the respective working temperature.

[0022] Protein synthesis in such batch reactions can only be maintained until the first important components are no longer functional due to degradation, inhibition or lack of energy. The biggest problem in this connection

is the energy supply for protein synthesis (Yao et al., 1997, Matveev et al., 1996) which is why only relatively short synthesis times can be achieved in these batch reactions and hence only relatively low yields of target protein (on average 0.1 - 20 µg/ml) (Mosca et al., 1983).

[0023] However, the mRNA required for protein synthesis can also be produced directly in the expression systems. For these so-called coupled transcription/translation systems it is possible to use the endogenous RNA polymerase as well as exogenous phage RNA polymerases to prepare the mRNA in systems based on *E. coli* lysates (Chen and Zubay, 1983; Köhrer et al., 1996). In contrast exogenous phage RNA polymerases are used in eukaryotic systems (Craig et al., 1992; Baranov and Spirin, 1993). But then of course appropriate DNA templates with corresponding promoter elements are required in such eukaryotic systems.

[0024] The problem of short expression times and of the energy supply to the systems was solved with the *continuous exchange cell free translation apparatus* (CECF) or continuous flow cell-free translation apparatus (Spirin et al., 1988; Spirin, 1991). The fundamental idea is based on the continuous supply of energy and low-molecular components to the reaction and the continuous removal of low-molecular byproducts. In this connection the reaction is supplied via a semi-permeable membrane from a separate feed compartment.

[0025] The *in vitro* translation system is preferably a coupled *in vitro* transcription/translation system. The coupled *in vitro* transcription/translation preferably occurs in a CFCF or CEFC reactor.

[0026] Vectors or DNA templates can be used for the co-expression in *in vitro* transcription/translation systems whose structure corresponds to the expression vectors of the target proteins. In systems based on *E. coli* lysates it is possible to use promoters for the endogenous *E. coli* RNA polymerase as well as vectors containing promoters for exogenous viral polymerases. In this connection the vectors should also contain a ribosomal binding site and suitable terminator regions in addition to the promoter regions. In principle it is also possible to use linear DNA expression templates (e.g. PCR product). If circular expression vectors are used which have to be previously amplified *in vivo* before being used experimentally, they should contain suitable replication starting points and at least one selectable marker. The co-expression time period and the co-expression strength of chaperones can be optimized for the respective substrate proteins (Lottspeich and Zorbas, 1998).

[0027] In order to ensure a maximum efficiency of the chaperone machinery during the synthesis reaction, the co-expression should be regulated. An appropriate regulation can be achieved, on the one hand, by the metered addition of the co-expression vectors or, on the other hand, by regulatory sequences in the promoter regions of the vector which can regulate the induction and strength of the expression. IPTG-inducible lac-operator sequences, binding sequences for tetracycline repres-

sors or catabolite-inducible regulatory sequences (e.g. arabinose operator) can be used for such a regulation. However, in this connection separate induction of the target protein expression and of the chaperone co-expression must be taken into consideration.

[0028] Hence it is preferable to regulate the co-expression of the folding helper proteins or of the chaperones. In particular it is preferred that the expression of the target proteins can be induced separately from the co-expression of the folding helper proteins or of the co-chaperones.

[0029] DNA templates for eukaryotic systems should also be composed of appropriate promoter regions for viral RNA polymerases, the eukaryotic sequences required to initiate translation and suitable terminators. Circular expression vectors that have to be amplified in *E. coli* for their experimental use, should also contain a replication start sequence for *E. coli* and at least one selectable marker in *E. coli*. In this case it was also possible to regulate the chaperone co-expression by appropriate regulatory sequences for viral promoters (Lottspeich and Zorbas, 1998).

[0030] Since the overloading of the chaperone machinery depends on the respective target protein and the rate of expression of the target protein, the amount of required chaperones depends strongly on the target protein. Hence in individual cases it may be important to optimize the expression rates of both expression templates. Such an optimization can be achieved by varying the amount of expression template used in addition to the direct regulation of expression via promoters. In the case of target proteins that are very susceptible to aggregation it may indeed be necessary to use a large excess of chaperones whereas for other target proteins the strong co-expression of chaperones could even interfere with the expression of the target protein. Depending on the target protein, its functional expression may require the co-expression of single chaperones as well as the co-expression of several chaperones. In this connection it should also be noted that most chaperones only work effectively as complex systems with corresponding co-chaperones. Hence the co-expression of chaperones and appropriate co-chaperones is particularly preferred.

[0031] The object according to the invention can also be achieved by adding purified chaperones and co-chaperones in the required amount. However, this process is relatively expensive.

[0032] A further subject matter of the present invention is the use of a vector containing a gene coding for a folding helper protein for the method according to the invention. Another subject matter of the present invention is the use of a vector containing a gene coding for a co-chaperone for the method according to the invention.

[0033] A special subject matter of the present invention is the use of a vector containing a gene coding for a folding helper protein and additionally containing a

promoter region, a ribosomal binding site and a terminator region for the method according to the invention. It is also particularly preferable to use a vector containing a gene coding for a co-chaperone and additionally containing a promoter region, a ribosomal binding site and a terminator region for the method according to the invention.

[0034] In the following examples the method according to the invention is carried out in a rapid translation system (RTS system) using mitochondrial citrate synthase as the target protein (porcine heart; EC 4.1.3.7). GFP was used as another target protein. Unexpectedly co-expression of GroEL/ES in the RTS system as well as the addition of GroEL/ES led to an increase in the expression yields on a preparative scale.

Figure legends

[0035] Figure 1: Influence of GroEL/ES on the yield of active, purified CS in the RTS system: CS expression of pIVEX 2.4b without addition of GroEL/ES. CS expression of pIVEX 2.4b, co-expression of GroEL/ES. CS expression of pIVEX 2.4b with addition of 150 nM purified GroEL and 300 nM purified GroES.

[0036] Figure 2: Influence of Hsp70 and Hsp40 on the yield of GFP in the RTS system: GFP expression without addition of Hsp70 (from humans) and Hdj1 (Hsp40 from humans). GFP expression with co-expression of Hsp70 and Hdj1. GFP expression with addition of 300 nM Hsp70 and 300 nM Hdj1.

Bibliography

[0037]

Abavaya K, Myers MP, Murphy SP, Morimoto RI (1992) *Genes Dev* 6: 1153-1164.

Amrein KE, Takacs B, Stieger M, Molonos J, Flint NA, Burn P (1995) *Proc Natl Acad*

Arrigo AP, Suhan JP, Welch WJ (1988) *Mol Cell Biol* 8: 5059-5071

Baranov VI, Spirin AS (1993) *Methods Enzymol* 217: 123-142

Beckman RP, Mizzen LE, Welch WJ (1990) *Science* 248: 850-854

Beissinger M, Buchner J (1998) *Biol Chem* 379, 245-259

Bergman L, Köhl WM (1979) *J Biol Chem* 267: 6786-6800

Bohen SP, Kralli A, Yamamoto KR (1995) *Science* 268: 1303-1304

Braakman I, Hoover-Litty H, Wagner KR, Helenius A (1991) *J Cell Biol* 114: 401-411

Buchner J (1996) *FASEB J* 10: 10-19

Buchner J (1999) *Trends Biochem Sci* 24: 136-141

Bukau B, Horwich AL (1998) *Cell* 92: 351-66

Chen HZ, Zubay G (1983) *Methods Enzymol* 101: 674-690

Craig EA (1992) in: *The Molecular and Cellular Biology of the Yeast S. cerevisiae*. Jones EW (Editor) Cold Spring Harbor Laboratory Press, New York, 501-537

Dale GE, Schönfeld HJ, Langen, Stieger M (1994) *Protein Eng* 7: 925-931

Dekker PJT, Pfanner N (1999) in: *Molecular Chaperones and folding Catalysts*, Bukau B (Editor), Harwood Academic publishers, 235-263

Egers DK, Welch WJ, Hansen WJ (1997) *Mol Biol Cell* 8: 1559-1573

Ehrnsperger M, Graber S, Gaestel M, Buchner J (1997) *EMBO J* 16: 221-229

Ehrnsperger M, Hergersberg C, Wienhues U, Nichtl A, Buchner J (1998) *Anal Biochem* 259: 218-225

Ewalt KL, Hendrick JP, Houry WA, Hartl FU (1997) *Cell* 90: 491-500

Falk MM, Buehler LK, Kumar NM, Gilula NB (1997) *EMBO J* 16: 2703-2716

Fenton WA, Kashi Y, Furtak K, Horwich A (1994) *Nature* 371, 614-619

Frydman J, Nimmersgern, Ohstuka K, Hartl FU (1994) *Nature* 370: 11-117

Ganea E, Harding JJ (1995) *Eur J Biochem* 231: 181-185

Georgopoulos C, Welch WJ (1993) *Annu Rev Cell Biol* 9: 601-634

Gething MJ, Sambrook JF (1992) *Nature* 355: 33-45

Gottesman S, Maurizi MR, Wickner S (1997) *Cell* 91: 435-438

Goloubinoff P, Gatenby AA, Lorimer GH (1989) *Na-*

ture 337: 44-47

Goloubinoff P, Mogk A, Zvi AP, Tomoyasu T, Bukau B (1999) *Proc Natl Acad Sci USA* 96: 13732-13737

Grangerov AI, Martin ES, Krupenko MA, Kashlev MV, Nikiforov VG (1991) *FEBS Lett* 291: 22-224

Gutsche I, Essen LO, Baumeister W (1999) *J Mol Biol* 293: 295-312

Hannavy K, Rospert S, Schatz G (1993) *Curr Opin Cell Biol* 5: 694-700

Hansen WJ, Lingappa VR, Welch WJ (1994) *J Biol Chem* 269: 26610-26613

Hartl FU (1996) *Nature* 381: 571-579

Hartl FU (1998) *Biol Chem* 379: 235-240

Hauke V, Schatz G (1997) *EMBO J* 16: 4560-4567

Hendrick JP, Hartl FU (1993) *Annu Rev Biochem* 62: 349-384

Horwitz J (1992) *Proc Natl Acad Sci* 89: 10449-10453

Horwitz J, Bova MP, Ding LL, Haley DA, Stewart PL (1999) *Eye* 13: 403-408

Huppa JB, Ploegh HL (1997) *J Exp Med* 186: 393-403

Jaenicke R (1997) in: *Molecular Chaperones in the Life Cycle of Proteins*. Fink AL, Goto Y, (Editor), Marcel Dekker, New York, 35-70

Jaenicke R, Creighton TE (1993) *Curr Biol* 3: 234-235

Jaenicke R, Rudolph R (1986) *Methods Enzymol* 131: 218-250

Jaenicke R, Rudolph R (1989) in: *Protein Structure: A Practical Approach*. Creighton TE (Editor), IRL Press, Oxford, 191-223

Jakob U, Gaestel M, Engel K, Buchner J (1993) *J Biol Chem* 268: 1517-1520

Jakob U, Buchner J (1994) *Trends Biochem Sci* 19: 205-211

Kiefhaber T, Rudolph R, Kohler HH, Buchner J (1991) *Bio/Technology* 9: 825-829

Köhler C, Mayer C, Grübner P, Piendl W (1996) *Eur J Biochem* 236: 234-239

Kruger E, Volker U, Hecker M (1994) *J Bacteriol* 176: 3360-3367

Lee GJ, Pokala N, Vierling E (1995) *J Biol Chem* 270: 10432-10438

Lee GJ, Roseman AM, Saibil HR, Vierling E (1997) *EMBO J* 16: 659-671

Lillie H, McLaughlin S, Freedman RB, Buchner J (1994) *J Biol Chem* 269: 14290-14296

Liou AK, Willison KR (1997) *EMBO J* 16: 4311-4361

Lorimer GH (1996) *FASEB J* 10: 5-9

Lottspeich F, Zorbas H (1998) *Bioanalytik (Hrsg.) Spektrum Verlag, Berlin*

Matveev SV, Vnokurov LM, Shaloiko LA, Matveeva EA, Alakhov YB (1996) *Biochim Biophys Acta* 1293: 207-212

Mosca JD, Wu JM, Suhadolnik PJ (1983) *Biochemistry* 22: 346-354

Parsell DA, Kowal AS, Singer MA, Lindquist S (1994) *Nature* 372: 475-478

Pelham HRB, Jackson RJ (1976) *Eur J Biochem* 67: 247-256

Peters T Jr, Davidson LK (1982) *J Biol Chem* 257: 8847-8853

Schatz G, Doberstein B (1996) *Science* 271: 1519-1526

Schirmer EC, Lindquist S, Vierling E (1994) *Plant Cell* 6: 1899-1909

Schmidt M, Bucheler U, Kaluza B, Buchner J (1994) *J Biol Chem* 269: 27964-27972

Schmid FX (1997) in: *Protein Structure: A Practical Approach*. Creighton RE (Editor) IRL Press, Oxford, 253-299

Sigler PB, Xu Z, Rye HS, Burston SG, Fenton WA, Horwich AL (1998) *Annu Rev Biochem* 67: 581-608

Spector A, Li LK, Augusteyn RC, Schneider A, Freund T (1971) *Biochem J* 124: 337-343

Spirin AS, Baranov VI, Ryabova LA, Ovodov SY,

Alakhov YB (1988) *Science* 242: 1162-1164

Spirin AS (1990) in: *The Ribosome: Structure, Funktion and Evolution*. Hill EH, Dahlberg A Garrot RA, Moore PB, Schlessinger D, Warrner JR, Washington DC (Editors) American Society for Microbiology, 56-70

Spirin AS (1991) in: *Frontiers in Bioprocessing II*. Todd P, Skidar SK, Bier M, Washington DC (Editors) American Chemical Society, 31-43

Stiege W, Erdman VA (1995) *J Biotechnol* 1995 41: 81-90

Sullivan W, Stensgard B, Caucutt G, Bartha B, McMahon N, Alnemri ES, Litwack G, Toft D (1997) *J Biol Chem* 272: 8007-8012

Tulin EE, Ken-Ichi T, Shin-Ichiro E (1995) *Biotechnol Bioeng* 45: 511-516

Vickery LE, Silberg JJ, Ta DT (1997) *Protein Sci* 6: 1047-1056

Welch WJ, Feramisco JR (1982) *J Biol Chem* 257: 14949-14959

Welch WJ, Eggers DK, Hansen WJ, Nagata H (1997) in: *Molecular Chaperones in Life Cycle of Proteins*. Fink AL, Goto Y (Editors) Marcel Dekker, New York, 71-93

Weissman JS, Kim PS (1993) *Nature* 365, 185-188

Wunderlich M, Glockshuber R (1993) *Prot Sci* 2: 717-726

Yao SL, Shen XC, Suzuki E (1997) *J Ferment Bioeng* 84: 7-13

Zubay G (1973) *Annu Rev Genet* 7: 267-287

Example 1:

[0038] A pIVEX 2.4b vector (Roche, Molecular Biochemicals) containing the citrate synthase gene was used for expression in the RTS system which expresses the citrate synthase gene with a His-tag fused to the N-terminus. The reactions were carried out for 24 h at 27°C, 140 rpm using RTSmini kits of lot No. 85869220 (Roche, Molecular Biochemicals).

[0039] The aggregation of the expressed citrate synthase was suppressed by, on the one hand, co-expressing GroEL/ES and, on the other hand, by adding purified GroEL/ES to the RTS reactions.

[0040] 8 µg pIVEX 2.4b and 8 µg of the GroEL/ES-expressing plasmid was used in each case. The GroEL/

ES-expressing plasmid corresponds to a modified pET vector (Novagen, Milwaukee, USA) which expresses the GroEL/ES operon under the control of a T7 promoter (Ishii Yasuhawa et al., 1995). The expression of the 3 proteins was checked with SDS-PAGE and immunoblot. All proteins are expressed in approximately equal amounts.

[0041] The GroEL/ES used for the addition, was purified as described in Schmidt et al., (1994). 150 nM GroEL and 300 nM GroES were added to the RTS system.

[0042] After completion of the RTS reaction, the reaction mixtures were centrifuged for 10 min at 14000 g and 4°C in order to separate aggregates from the soluble components. The soluble fraction was diluted 1:10 with Ni-NTA equilibration buffer (100 mM Na₂HPO₄, 300 mM NaCl, pH 7.4) and loaded at a continuous flow rate of 0.5 ml/min onto a 1 ml Ni-NTA Superflow column (Quiagen). The column was firstly washed with 5 ml equilibration buffer and subsequently with 5 ml washing buffer (100 mM Na₂HPO₄, 300 mM NaCl, 30 mM imidazole, pH 6.8). The citrate synthase was then eluted from the column with 3 ml elution buffer (100 mM Na₂HPO₄, 300 mM NaCl, 300 mM imidazole, pH 7.5).

[0043] Co-enzyme A that is formed as a byproduct of the condensation of oxaloacetate stoichiometrically reduces Ellman's reagent (DNTB) which is associated with an increase in the absorption at 412 nm. Correctly folded active citrate synthase can be detected with this reaction. For the activity determination 50 µl of the purified citrate synthase (elution fraction), 900 µl TE buffer (50 mM Tris/HCl, 2 mM EDTA, pH 8.0), 10 µl oxaloacetate (10 mM in 50 mM Tris), 10 ml DTNB (in TE buffer) and 30 µl acetyl-CoA (in TE buffer) were mixed and incubated at 25°C. The change in absorbance was measured continuously over a period of 5 min and the change in absorbance per minute was determined. The change in absorbance of purified citrate synthase was averaged in each case from three different RTS reactions. The averaged absorbance change in the RTS reactions without GroEL/ES co-expression was normalized to 1.

Result:

[0044] As shown in figure 1 both approaches lead to high yields of active purified mitochondrial citrate synthase. Surprisingly the co-expression of the GroEL/ES system worked just as well as the direct addition of purified GroEL and GroES. The yield of active purified target protein was increased 5-fold by the co-expression of GroEL/ES.

Example 2:

[0045] GFP was used as a model substrate to examine the effects of Hsp70 chaperones on expression in the RTS system. The reactions were carried out for 24 h at 27°C, 140 rpm using the RTSmini kit lot No.

85869220 (Roche, catalogue). In order to ensure that GFP was oxidized during the reaction, only half amounts were used. In each case 5 µg of the GFP control plasmid contained in the RTSmini kit was used.

[0046] In order to examine the effects of Hsp70 on the expression yield in the system, human Hsp70 and Hsp40 were co-expressed, and on the other hand, purified Hsp70 and Hsp40 were added to the RTS reactions.

[0047] 8 µg of the Hsp70 and Hsp40 expression plasmids were used in each case. The Hsp70-expressing plasmid corresponds to a pET11a vector (Novagen, Milwaukee, USA), the Hsp40 (Hdj1) expressing plasmid corresponds to a pET21d vector (Novagen, Milwaukee, USA), both genes were expressed under the control of a T7 promoter. 300 nM Hsp70 and 300 nM Hdj1 were added to the RTS system (Abravaya et al., 1992).

[0048] After completion of the RTS reaction, the reaction mixtures were centrifuged for 10 min at 14000 g and 4°C to separate the aggregates from the soluble components. The fluorescence emission of the soluble fractions was measured at 430-580 nm at an excitation of 395 nm. The relative fluorescence at 503 nm of the mixture without addition or co-expression of chaperones was normalized to 1 and compared to the fluorescence of the mixtures containing chaperones. In order to exclude the effects of the subsequent oxidation of GFP, the samples were measured again after 24 hours but no differences were observed.

Result:

[0049] As shown in figure 2, both approaches lead to high yields of active GFP. Surprisingly the addition as well as the co-expression of Hsp70 chaperones worked. The yield of active target protein was doubled by the co-expression of Hsp70 and Hsp40. Direct addition led to an increase of the yield by more than 3-fold.

Claims

1. Method for the expression of target proteins in *in vitro* translation systems, **characterized in that** folding helper proteins are co-expressed in this system.
2. Method as claimed in claim 1, **characterized in that** the co-expressed folding helper proteins are selected from one or several of the following protein classes: Hsp60, Hsp70, Hsp90, Hsp100 protein family, family of small heat shock proteins and isomerases.
3. Method as claimed in claim 1 or 2, **characterized in that** the co-expressed folding helper proteins are members of the Hsp60 protein family.

4. Method as claimed in claim 3, **characterized in that** co-chaperones are additionally co-expressed.
5. Method as claimed in claim 4, **characterized in that** Hsp60 is co-expressed as the folding helper protein and Hsp10 is co-expressed as the co-chaperone.
6. Method as claimed in one of the claims 3-5, **characterized in that** the co-expressed folding helper protein is GroEL.
7. Method as claimed in one of the claims 4-6, **characterized in that** GroEL/ES are co-expressed.
8. Method as claimed in claim 1 or 2, **characterized in that** the co-expressed folding helper proteins are members of the Hsp70 protein family.
9. Method as claimed in claim 8, **characterized in that** co-chaperones are additionally co-expressed.
10. Method as claimed in claim 8 or 9, **characterized in that** the co-expressed folding helper protein is a human Hsp70 protein.
11. Method as claimed in claim 9 or 10, **characterized in that** Hsp70 is co-expressed as a folding helper protein and Hsp40 is co-expressed as a co-chaperone.
12. Method as claimed in one of the claims 10-11, **characterized in that** Hsp70 from humans and Hdj1 (Hsp40 from humans) are co-expressed.
13. Method as claimed in one of the claims 1-12, **characterized in that** the *in vitro* translation system is a coupled *in vitro* transcription/translation system.
14. Method as claimed in one of the claims 1-13, **characterized in that** the co-expression of the folding helper proteins and/or of the co-chaperones is regulated.
15. Method as claimed in claim 14, **characterized in that** the expression of the target proteins can be induced separately from the co-expression of the folding helper proteins or of the co-chaperones.
16. Method as claimed in one of the claims 1-15, **characterized in that** the coupled *in vitro* transcription/translation takes place in a CFCF or CEFC reactor.
17. Use of a vector containing a gene coding for a folding helper protein for a method as claimed in one of the claims 1-16.
18. Use of a vector containing a gene coding for a co-

chaperone for a method as claimed in one of the claims 1-16.

19. Use of a vector containing a gene coding for a folding helper protein and additionally containing a promoter region, a ribosomal binding site and a terminator region for a method as claimed in one of the claims 1-16. 5
20. Use of a vector containing a gene coding for a co-chaperone and additionally containing a promoter region, a ribosomal binding site and a terminator region for a method as claimed in one of the claims 1-16. 10

15

20

25

30

35

40

45

50

55




Figure 1




Figure 2



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 00 9650

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	WO 94 24303 A (RES DEV FOUNDATION ; KUDLICKI WIESLAW (US); KRAMER GISELA (US); HAR) 27 October 1994 (1994-10-27) * page 2 - page 3 * * page 4, line 33 - page 5, line 2 * * page 10, line 8 - line 17; examples 12,13,15; tables 7-9 *	1-20	C12P21/02 C12N15/67
Y	WO 00 08135 A (GERON CORP ; WHITE MICHAEL A (US)) 17 February 2000 (2000-02-17) * examples 3,8 *	1,2,8-12	
Y	MATTS R L ET AL: "THE RELATIONSHIP BETWEEN PROTEIN SYNTHESIS AND HEAT SHOCK PROTEINS LEVELS IN RABBIT RETICULOCYTE LYSATES" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 25, 1992, pages 18168-18174, XP002202578 ISSN: 0021-9258 * page 18173, right-hand column, paragraph 4 - page 18174, left-hand column, paragraph 1; figures 2,4; tables 3,4 *	1-20	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12P
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 19 June 2002	Examiner van Heusden, M
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1503 03-82 (P04011)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 00 9650

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
P, Y	JIANG X ET AL: "Expression of Fab fragment of catalytic antibody 6D9 in an Escherichia coli in vitro coupled transcription/translation system" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 514, no. 2-3, 18 February 2002 (2002-02-18), pages 290-294, XP004347714 ISSN: 0014-5793 * page 291, left-hand column, paragraph 5 * * page 292, right-hand column, line 4 - page 293, right-hand column, line 2; figure 6 *	1-4, 6, 7, 13, 17-20	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	TYEDMERS JENS ET AL: "Assembly of heterodimeric luciferase after de novo synthesis of subunits in rabbit reticulocyte lysate involves Hsc70 and Hsp40 at a post-translational stage." EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 267, no. 12, June 2000 (2000-06), pages 3575-3582, XP002202579 ISSN: 0014-2956 * page 3576, left-hand column, paragraph 3 *	1, 2, 8-13	
Y	STIEGER ET AL: "The production of soluble recombinant proteins in E. coli assisted by molecular chaperones" IMMUNOLOGY METHODS MANUAL, XX, XX, October 1996 (1996-10), pages 40-44, XP002135427 * the whole document * ----- -/--	1-20	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 19 June 2002	Examiner van Heusden, M
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons & : member of the same patent family, corresponding document			

EPO-MUNICH 1505 03 52 (F04C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 00 9650

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	EP 0 774 512 A (IMANAKA TADAYUKI) 21 May 1997 (1997-05-21) * examples 1-3,8-11 *	1-20	
Y	EP 1 016 724 A (HSP KENKYUSHO KK) 5 July 2000 (2000-07-05) * figures 1,2; examples 3-6 *	1-7,14, 15,17-20	
Y	WO 93 25681 A (UNIV NEW YORK) 23 December 1993 (1993-12-23) * example 6 *	1,2,14, 15,17-20	
Y	EP 0 885 967 A (HSP KENKYUSHO KK) 23 December 1998 (1998-12-23) * claims 1-3,6,10-12; example 8 *	1,2,14, 15,17-20	
Y	RYABOVA L A ET AL: "CONTINUOUS-FLOW CELL-FREE TRANSLATION, TRANSCRIPTION-TRANSLATION, AND REPLICATION-TRANSLATION SYSTEMS", METHODS IN MOLECULAR BIOLOGY, HUMANA PRESS INC., CLIFTON, NJ, US, VOL. 77, PAGE(S) 179-193 XP001023038 * the whole document *	16	
A	FINK A L: "CHAPERONE-MEDIATED PROTEIN FOLDING" PHYSIOLOGICAL REVIEWS, AMERICAN PHYSIOLOGICAL SOCIETY, US, vol. 79, no. 2, April 1999 (1999-04), pages 425-449, XP000951465 ISSN: 0031-9333 * the whole document *	1-20	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
MUNICH		19 June 2002	van Heusden, M
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application C : document cited for other reasons % : member of the same patent family, corresponding document			

EPO FORM 1503 33 82 (POC01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 00 9650

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-06-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9424303	A	27-10-1994	AU 693443 B2	02-07-1998
			AU 6628894 A	08-11-1994
			CA 2159899 A1	27-10-1994
			EP 0693131 A1	24-01-1996
			JP 8508651 T	17-09-1996
			NZ 265504 A	25-09-1996
			WO 9424303 A1	27-10-1994
			ZA 9402335 A	05-10-1995
WO 0008135	A	17-02-2000	AU 5338199 A	28-02-2000
			WO 0008135 A1	17-02-2000
EP 0774512	A	21-05-1997	JP 9173078 A	08-07-1997
			EP 0774512 A2	21-05-1997
EP 1016724	A	05-07-2000	JP 2000189163 A	11-07-2000
			EP 1016724 A2	05-07-2000
			US 6197547 B1	06-03-2001
WO 9325681	A	23-12-1993	WO 9325681 A1	23-12-1993
EP 0885967	A	23-12-1998	JP 11009274 A	19-01-1999
			CA 2235468 A1	20-12-1998
			EP 0885967 A2	23-12-1998
			US 6159708 A	12-12-2000

E-P-U FORM P0439

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82